NCT04939402View on ClinicalTrials.gov

SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

May 31, 2028

Study Completion Date

June 30, 2028

Conditions
SARS-CoV-2Covid19
Interventions
DIAGNOSTIC_TEST

Serological testing

Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity

Trial Locations (1)

1090

RECRUITING

UZ Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER